Do analysts rate IDHC or DXRX?

Diaceutics has a consensus price target of GBX 215, suggesting a potential upside of 48.28%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than Integrated Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Integrated Diagnostics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate ABDX or DXRX?

Diaceutics has a consensus price target of GBX 215, suggesting a potential upside of 48.28%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than Abingdon Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abingdon Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer DXRX or GDR?

Diaceutics currently has a consensus price target of GBX 215, suggesting a potential upside of 48.28%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than genedrive. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 genedrive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, DXRX or GDR?

Diaceutics has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Diaceutics £38.44M 3.19 -£2.84M £0.11 1,318.18 genedrive £929K 23.57 -£21.22M -£0.79 N/A

Is DXRX or GDR more profitable?

Diaceutics has a net margin of 0.25% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of 0.25% beat genedrive's return on equity. Company Net Margins Return on Equity Return on Assets Diaceutics 0.25% 0.25% -6.06% genedrive -500.75% -1,044.57% -74.09%

Does the media favor DXRX or GDR?

In the previous week, Diaceutics and Diaceutics both had 1 articles in the media. genedrive's average media sentiment score of 0.68 beat Diaceutics' score of -0.54 indicating that genedrive is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Diaceutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative genedrive 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer YGEN or DXRX?

Diaceutics has a consensus target price of GBX 215, suggesting a potential upside of 48.28%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts plainly believe Diaceutics is more favorable than Yourgene Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Yourgene Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend AGL or DXRX?

Diaceutics has a consensus price target of GBX 215, indicating a potential upside of 48.28%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts plainly believe Diaceutics is more favorable than ANGLE. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ANGLE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger valuation and earnings, AGL or DXRX?

Diaceutics has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ANGLE £2.62M 2.89 -£21.76M -£4.80 N/A Diaceutics £38.44M 3.19 -£2.84M £0.11 1,318.18

Is AGL or DXRX more profitable?

Diaceutics has a net margin of 0.25% compared to ANGLE's net margin of -1,444.04%. Diaceutics' return on equity of 0.25% beat ANGLE's return on equity. Company Net Margins Return on Equity Return on Assets ANGLE -1,444.04% -191.36% -29.89% Diaceutics 0.25% 0.25% -6.06%

Does the media favor AGL or DXRX?

In the previous week, ANGLE and ANGLE both had 1 articles in the media. ANGLE's average media sentiment score of 0.00 beat Diaceutics' score of -0.54 indicating that ANGLE is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANGLE 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Diaceutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Diaceutics (DXRX) Competitors

GBX 145 +1.50 (+1.05%)

As of 11:50 AM Eastern

Compare

DXRX vs. IDHC, ABDX, GDR, YGEN, and AGL

Should you buy Diaceutics stock or one of its competitors? Diaceutics's main competitors and comparable companies include Integrated Diagnostics (IDHC), Abingdon Health (ABDX), genedrive (GDR), Yourgene Health (YGEN), and ANGLE (AGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Diaceutics compare to Integrated Diagnostics?

Integrated Diagnostics (LON:IDHC) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

7.7% of Integrated Diagnostics shares are owned by institutional investors. Comparatively, 32.6% of Diaceutics shares are owned by institutional investors. 71.3% of Integrated Diagnostics shares are owned by company insiders. Comparatively, 26.3% of Diaceutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Integrated Diagnostics has higher revenue and earnings than Diaceutics. Integrated Diagnostics is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated Diagnostics	£8.35B	0.00	£4.01T	£250.03	0.00
Diaceutics	£38.44M	3.19	-£2.84M	£0.11	1,318.18

Diaceutics has a consensus price target of GBX 215, suggesting a potential upside of 48.28%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than Integrated Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integrated Diagnostics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Diaceutics had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 1 mentions for Diaceutics and 0 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.00 beat Diaceutics' score of -0.54 indicating that Integrated Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Integrated Diagnostics	Neutral
Diaceutics	Negative

Integrated Diagnostics has a net margin of 17.20% compared to Diaceutics' net margin of 0.25%. Integrated Diagnostics' return on equity of 38.79% beat Diaceutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integrated Diagnostics	17.20%	38.79%	9.69%
Diaceutics	0.25%	0.25%	-6.06%

Integrated Diagnostics has a beta of 0.436, indicating that its share price is 56% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.886, indicating that its share price is 11% less volatile than the broader market.

Summary

Integrated Diagnostics and Diaceutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Diaceutics compare to Abingdon Health?

Abingdon Health (LON:ABDX) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Abingdon Health has a beta of 0.132, indicating that its stock price is 87% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.886, indicating that its stock price is 11% less volatile than the broader market.

3.7% of Abingdon Health shares are held by institutional investors. Comparatively, 32.6% of Diaceutics shares are held by institutional investors. 8.0% of Abingdon Health shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Diaceutics had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for Diaceutics and 0 mentions for Abingdon Health. Abingdon Health's average media sentiment score of 0.00 beat Diaceutics' score of -0.54 indicating that Abingdon Health is being referred to more favorably in the media.

Company	Overall Sentiment
Abingdon Health	Neutral
Diaceutics	Negative

Diaceutics has a net margin of 0.25% compared to Abingdon Health's net margin of -33.88%. Diaceutics' return on equity of 0.25% beat Abingdon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abingdon Health	-33.88%	-55.91%	-17.93%
Diaceutics	0.25%	0.25%	-6.06%

Abingdon Health has higher earnings, but lower revenue than Diaceutics. Abingdon Health is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abingdon Health	£9.57M	2.76	-£796.37K	-£0.81	N/A
Diaceutics	£38.44M	3.19	-£2.84M	£0.11	1,318.18

Diaceutics has a consensus price target of GBX 215, suggesting a potential upside of 48.28%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than Abingdon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abingdon Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Diaceutics beats Abingdon Health on 14 of the 16 factors compared between the two stocks.

How does Diaceutics compare to genedrive?

Diaceutics (LON:DXRX) and genedrive (LON:GDR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

32.6% of Diaceutics shares are held by institutional investors. Comparatively, 0.1% of genedrive shares are held by institutional investors. 26.3% of Diaceutics shares are held by insiders. Comparatively, 29.0% of genedrive shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Diaceutics has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£38.44M	3.19	-£2.84M	£0.11	1,318.18
genedrive	£929K	23.57	-£21.22M	-£0.79	N/A

In the previous week, Diaceutics and Diaceutics both had 1 articles in the media. genedrive's average media sentiment score of 0.68 beat Diaceutics' score of -0.54 indicating that genedrive is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Diaceutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
genedrive	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Diaceutics has a beta of 0.886, indicating that its share price is 11% less volatile than the broader market. Comparatively, genedrive has a beta of 0.989, indicating that its share price is 1% less volatile than the broader market.

Diaceutics has a net margin of 0.25% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of 0.25% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	0.25%	0.25%	-6.06%
genedrive	-500.75%	-1,044.57%	-74.09%

Diaceutics currently has a consensus price target of GBX 215, suggesting a potential upside of 48.28%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than genedrive.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
genedrive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Diaceutics beats genedrive on 11 of the 15 factors compared between the two stocks.

How does Diaceutics compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Yourgene Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.886, suggesting that its share price is 11% less volatile than the broader market.

Diaceutics has a consensus target price of GBX 215, suggesting a potential upside of 48.28%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts plainly believe Diaceutics is more favorable than Yourgene Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yourgene Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

23.3% of Yourgene Health shares are held by institutional investors. Comparatively, 32.6% of Diaceutics shares are held by institutional investors. 64.4% of Yourgene Health shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Diaceutics had 1 more articles in the media than Yourgene Health. MarketBeat recorded 1 mentions for Diaceutics and 0 mentions for Yourgene Health. Yourgene Health's average media sentiment score of 0.00 beat Diaceutics' score of -0.54 indicating that Yourgene Health is being referred to more favorably in the media.

Company	Overall Sentiment
Yourgene Health	Neutral
Diaceutics	Negative

Diaceutics has higher revenue and earnings than Yourgene Health. Yourgene Health is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A
Diaceutics	£38.44M	3.19	-£2.84M	£0.11	1,318.18

Diaceutics has a net margin of 0.25% compared to Yourgene Health's net margin of -27.55%. Diaceutics' return on equity of 0.25% beat Yourgene Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yourgene Health	-27.55%	-27.06%	-6.71%
Diaceutics	0.25%	0.25%	-6.06%

Summary

Diaceutics beats Yourgene Health on 13 of the 15 factors compared between the two stocks.

How does Diaceutics compare to ANGLE?

ANGLE (LON:AGL) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Diaceutics has a net margin of 0.25% compared to ANGLE's net margin of -1,444.04%. Diaceutics' return on equity of 0.25% beat ANGLE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANGLE	-1,444.04%	-191.36%	-29.89%
Diaceutics	0.25%	0.25%	-6.06%

17.5% of ANGLE shares are held by institutional investors. Comparatively, 32.6% of Diaceutics shares are held by institutional investors. 2.7% of ANGLE shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ANGLE has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.886, meaning that its stock price is 11% less volatile than the broader market.

Diaceutics has a consensus price target of GBX 215, indicating a potential upside of 48.28%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts plainly believe Diaceutics is more favorable than ANGLE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANGLE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Diaceutics has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A
Diaceutics	£38.44M	3.19	-£2.84M	£0.11	1,318.18

In the previous week, ANGLE and ANGLE both had 1 articles in the media. ANGLE's average media sentiment score of 0.00 beat Diaceutics' score of -0.54 indicating that ANGLE is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANGLE	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Diaceutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Diaceutics beats ANGLE on 14 of the 15 factors compared between the two stocks.

Get Diaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXRX vs. The Competition

Export

Metric	Diaceutics	Life Sciences Tools & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£122.71M	£10.21B	£7.40B	£2.92B
Dividend Yield	N/A	1.46%	2.53%	6.17%
P/E Ratio	1,318.18	63.20	272.19	367.32
Price / Sales	3.19	111.26	631.76	83,741.35
Price / Cash	3.12	27.09	79.89	27.89
Price / Book	3.16	37.51	13.14	7.02
Net Income	-£2.84M	£56.67B	£3.47B	£5.89B
7 Day Performance	1.40%	2.12%	1.38%	0.89%
1 Month Performance	13.28%	10.71%	8.62%	3.27%
1 Year Performance	5.45%	25.70%	25.90%	22.28%

Diaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXRX Diaceutics	1.6515 of 5 stars	GBX 145 +1.0%	GBX 215 +48.3%	+5.6%	£122.71M	£38.44M	1,318.18	151
IDHC Integrated Diagnostics	N/A	GBX 0.54 +5.9%	N/A	+27.0%	£313.92M	£8.35B	0.00	6,692	Gap Down
ABDX Abingdon Health	N/A	GBX 11.25 +2.3%	N/A	+86.5%	£27.80M	£9.57M	N/A	84	Gap Up
GDR genedrive	N/A	GBX 1.33 -1.5%	N/A	+59.1%	£21.68M	£929K	N/A	43	Positive News Gap Up
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:DXRX) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Diaceutics (DXRX) Competitors

DXRX vs. IDHC, ABDX, GDR, YGEN, and AGL

How does Diaceutics compare to Integrated Diagnostics?

Summary

How does Diaceutics compare to Abingdon Health?

Summary

How does Diaceutics compare to genedrive?

Summary

How does Diaceutics compare to Yourgene Health?

Summary

How does Diaceutics compare to ANGLE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Diaceutics (DXRX) Competitors

DXRX vs. IDHC, ABDX, GDR, YGEN, and AGL

How does Diaceutics compare to Integrated Diagnostics?

Do institutionals and insiders hold more shares of IDHC or DXRX?

Which has better earnings & valuation, IDHC or DXRX?

Do analysts rate IDHC or DXRX?

Does the media refer more to IDHC or DXRX?

Is IDHC or DXRX more profitable?

Which has more volatility & risk, IDHC or DXRX?

Summary

How does Diaceutics compare to Abingdon Health?

Which has more risk & volatility, ABDX or DXRX?

Do insiders & institutionals hold more shares of ABDX or DXRX?

Does the media refer more to ABDX or DXRX?

Is ABDX or DXRX more profitable?

Which has preferable earnings and valuation, ABDX or DXRX?

Do analysts rate ABDX or DXRX?

Summary

How does Diaceutics compare to genedrive?

Do institutionals & insiders have more ownership in DXRX or GDR?

Which has higher valuation & earnings, DXRX or GDR?

Does the media favor DXRX or GDR?

Which has more volatility & risk, DXRX or GDR?

Is DXRX or GDR more profitable?

Do analysts prefer DXRX or GDR?

Summary

How does Diaceutics compare to Yourgene Health?

Which has more volatility and risk, YGEN or DXRX?

Do analysts prefer YGEN or DXRX?

Do insiders and institutionals have more ownership in YGEN or DXRX?

Does the media favor YGEN or DXRX?

Which has preferable earnings and valuation, YGEN or DXRX?

Is YGEN or DXRX more profitable?

Summary

How does Diaceutics compare to ANGLE?

Is AGL or DXRX more profitable?

Do insiders & institutionals believe in AGL or DXRX?

Which has more volatility and risk, AGL or DXRX?

Do analysts recommend AGL or DXRX?

Which has stronger valuation and earnings, AGL or DXRX?

Does the media favor AGL or DXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools